Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
New York Prebyterian Hospital - Weill Cornell Medical College
mi
from
New York, NY
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
New York Prebyterian Hospital - Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis
Status: Enrolling
Updated:  1/21/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis
Status: Enrolling
Updated: 1/21/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Winship Cancer Center
mi
from
Atlanta, GA
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Winship Cancer Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Dana-Farber Cancer Center
mi
from
Boston, MA
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Dana-Farber Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
University of Michigan
mi
from
Ann Arbor, MI
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
St. Vincent's Comprehensive Cancer Center
mi
from
New York City, NY
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
St. Vincent's Comprehensive Cancer Center
mi
from
New York City, NY
Click here to add this to my saved trials
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
University of Colorado Health Sciences Center/Anschutz Cancer Pavilion
mi
from
Aurora, CO
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
University of Colorado Health Sciences Center/Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Rocky Mountain Cancer Center
mi
from
Denver, CO
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Northwestern University Clinical Research Office
mi
from
Chicago, IL
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Northwestern University Clinical Research Office
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Rush University Medical Center
mi
from
Chicago, IL
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
University of Chicago Hospital
mi
from
Chicago, IL
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
University of Chicago Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Indiana Blood and Marrow Institute/St. Francis Hospital
mi
from
Beech Grove, IN
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Indiana Blood and Marrow Institute/St. Francis Hospital
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
University of Michigan
mi
from
Ann Arbor, MI
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Mayo Clinic Cancer Center
mi
from
West Rochester, MN
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Mayo Clinic Cancer Center
mi
from
West Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Hackensack University Medical Center/Oncology Research Dept.
mi
from
Hackensack, NJ
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Hackensack University Medical Center/Oncology Research Dept.
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Duke University Hospital
mi
from
Durham, NC
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Oregon Health and Science University
mi
from
Portland, OR
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Emory University School of Medicine-Winship Cancer Institute
mi
from
Nashville, TN
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Emory University School of Medicine-Winship Cancer Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Vanderbilt University Medical Center Clinical Trials Center
mi
from
Nashville, TN
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Vanderbilt University Medical Center Clinical Trials Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Novartis Investigative Site
mi
from
Cologne,
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Novartis Investigative Site
mi
from
Cologne,
Click here to add this to my saved trials
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
A Phase II Study of Eltrombopag for the Treatment of Thrombocytopenia in Patients Undergoing Therapy for Relapsed Multiple Myeloma
Status: Enrolling
Updated:  1/22/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
A Phase II Study of Eltrombopag for the Treatment of Thrombocytopenia in Patients Undergoing Therapy for Relapsed Multiple Myeloma
Status: Enrolling
Updated: 1/22/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/25/2016
UCSD
mi
from
La Jolla, CA
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)
A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/25/2016
UCSD
mi
from
La Jolla, CA
Click here to add this to my saved trials
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
A Phase II Trial Evaluating the Safety and Efficacy of Plerixafor and Sargramostim (GM-CSF) for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal, HLA-Matched Allogeneic Sibling Donors
Status: Enrolling
Updated:  1/26/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
A Phase II Trial Evaluating the Safety and Efficacy of Plerixafor and Sargramostim (GM-CSF) for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal, HLA-Matched Allogeneic Sibling Donors
Status: Enrolling
Updated: 1/26/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Single Incision Versus Standard Laparoscopic Splenectomy
Single Incision Versus Standard Laparoscopic Splenectomy
Status: Enrolling
Updated:  1/27/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Single Incision Versus Standard Laparoscopic Splenectomy
Single Incision Versus Standard Laparoscopic Splenectomy
Status: Enrolling
Updated: 1/27/2016
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas
Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study
Status: Enrolling
Updated:  1/27/2016
Childrens National Medical Center
mi
from
Washington,
Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas
Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study
Status: Enrolling
Updated: 1/27/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/27/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/27/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Status: Enrolling
Updated:  1/27/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Status: Enrolling
Updated: 1/27/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Status: Enrolling
Updated:  1/27/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Status: Enrolling
Updated: 1/27/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Status: Enrolling
Updated:  1/27/2016
Dana-Farber Cancer Insitute
mi
from
Boston, MA
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Status: Enrolling
Updated: 1/27/2016
Dana-Farber Cancer Insitute
mi
from
Boston, MA
Click here to add this to my saved trials
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Status: Enrolling
Updated:  1/27/2016
Massachusetts General Hospital
mi
from
Boston, MA
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors
Status: Enrolling
Updated: 1/27/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials